SCHEMBL29776745

SCHEMBL29776745

Nc1ccc2ccccc2c1N=Nc1ccc(/C=C/c2ccc(N=Nc3c(N)ccc4ccccc34)cc2S(=O)(=O)O)c(S(=O)(=O)O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SENP2 Q9HC62 7/20 1.00
▸ SENP1 Q9P0U3 6/20 1.00
▸ SENP3 Q9H4L4 5/20 1.00
▸ SUMO2 P61956 5/20 1.00
▸ SUMO1 P63165 5/20 1.00
▸ SENP7 Q9BQF6 5/20 1.00
▸ GLO1 Q04760 3/20 0.50
▸ RAD1 O60671 1/20 0.48
▸ P2RY6 Q15077 1/20 0.48
▸ MAPT P10636 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ MPL P40238 3/20 0.47
▸ CTRC Q99895 2/20 0.47
▸ MEN1 O00255 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.41
▸ APP P05067 1/20 0.41
▸ THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059056 1.00 SENP2 (1.00) SENP2SENP1SENP3SUMO2SUMO1
SCHEMBL4059042 1.00 SENP2 (1.00) SENP2SENP1SENP3SUMO2SUMO1
SCHEMBL29555761 1.00 SENP2 (1.00) SENP2SENP1SENP3SUMO2SUMO1
Potassium Ion SCHEMBL30016826 0.87 SENP2 (0.78) SENP2SENP1SENP3SUMO2SUMO1
SCHEMBL26725585 0.84 SENP2 (0.72) SENP2SENP1SENP3SUMO2SUMO1
SCHEMBL26459366 0.83 SENP2 (0.71) SENP2SENP1SENP3SUMO2SUMO1
SCHEMBL6339124 0.81 SENP2 (1.00) SENP2SENP1SENP3SUMO2SUMO1
SCHEMBL29554795 0.81 SENP2 (1.00) SENP2SENP1SENP3SUMO2SUMO1
SCHEMBL29473545 0.81 SENP2 (1.00) SENP2SENP1SENP3SUMO2SUMO1
SCHEMBL3958375 0.81 SENP2 (1.00) SENP2SENP1SENP3SUMO2SUMO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025029578-A1 SUMOYLATION AS A THERAPEUTIC TARGET IN INFLAMMATORY BOWEL DISEASES AND INFECTIONS DISORDERS DUKE UNIVERSITY (US) 2025-02-06 — — WO claimed
US-20240358731-A1 SUMO PATHWAY AS AN OXYGEN SENSOR RELEVANT TO THE PATHOPHYSIOLOGY OF PULMONARY ARTERY HYPERTENSION AND CARDIAC ARRHYTHMIA NORTHEASTERN UNIVERSITY 2024-10-31 — — US claimed
CN-122016094-A Temperature compensation type crosstalk-proof capacitive sensing array acquisition circuit and control method 浪潮通用软件有限公司 2026-05-12 — — CN disclosed
WO-2025029578-A1 SUMOYLATION AS A THERAPEUTIC TARGET IN INFLAMMATORY BOWEL DISEASES AND INFECTIONS DISORDERS DUKE UNIVERSITY (US) 2025-02-06 — — WO disclosed
US-20240358731-A1 SUMO PATHWAY AS AN OXYGEN SENSOR RELEVANT TO THE PATHOPHYSIOLOGY OF PULMONARY ARTERY HYPERTENSION AND CARDIAC ARRHYTHMIA NORTHEASTERN UNIVERSITY 2024-10-31 — — US disclosed
US-20240058431-A1 NOVEL COMPOSITION THE UNIVERSITY OF LIVERPOOL (GB) 2024-02-22 — — US disclosed
CN-113220349-B Semantic ontology model-based adaptation method for instrument heterogeneous peripheral 重庆邮电大学 2022-09-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240358731-A1 SUMO PATHWAY AS AN OXYGEN SENSOR RELEVANT TO THE PATHOPHYSIOLOGY OF PULMONARY ARTERY HYPERTENSION AND CARDIAC ARRHYTHMIA SUMO1, SUMO2, SUMO3 SENP2 22/4885SENP1 10/4885SENP3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback